Investigating how genetics and ancestry affect asthma and COPD treatment responses
Official title: Effects of Rare Variants and Ancestry on Beta Agonist Response in Asthma and COPD
Funded at Mayo Clinic Arizona · NIH-10620284 · Data updated 2026-11-12
This study is looking at how your unique genes and background might affect how well asthma and COPD medications work for you, and it invites patients to share their genetic information to help find out more about this connection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | December 2, 2021 |
| Project end | December 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $674,066 |
| NIH project number | 5R01HL142992-05 |
| Project ID | NIH-10620284 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with asthma or COPD, particularly those of African American descent or from diverse ethnic backgrounds.
✕Less likely to help
Patients who do not have asthma or COPD, or those who do not have a genetic predisposition affecting their response to beta agonists may not benefit from this research.
What this research studies
This research explores the impact of rare genetic variants and ancestry on how patients with asthma and COPD respond to beta agonist medications. By analyzing genetic data from diverse patient groups, the study aims to identify specific genetic factors that influence treatment effectiveness and lung function. The approach includes both conventional genetic analysis and functional assessments to understand the role of ancestry-specific variations. Patients may be asked to provide genetic samples and participate in assessments to help uncover these important relationships.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for asthma and COPD patients based on their genetic background.
How similar studies have gone: Previous research has indicated that genetic factors can significantly influence treatment responses in asthma and COPD, suggesting that this study's approach is grounded in established findings.
Where this research is happening
-
Mayo Clinic Arizona
Scottsdale, United States Active
Researchers
- Principal investigator: Ortega, Victor E. — Mayo Clinic Arizona
- Study coordinator: Ortega, Victor E.
Related research
Other NIH-funded projects on the same topics.
-
Pennsylvania asthma-COPD syndromic surveillance for cleaner air and healthier kids
A Pennsylvanian health project is building a real-time warning system to help doctors and families spot spikes in asthma and COPD risks related to air pollution and smoke.
-
How climate change affects respiratory health in asthma and COPD patients
This study, led by Dr. Nicholas Nassikas, is looking at how changes in weather, like temperature and rainfall, affect the breathing health of people with asthma and COPD, especially in Black and Latinx communities, to find ways to help them feel better as our climate changes.
-
Understanding the link between asthma and COPD using advanced data analysis
This study is looking at how asthma and COPD are related, especially how things like being exposed to smoke before birth can affect lung health throughout life, and it's for anyone interested in understanding the biological factors that might influence these breathing conditions.
-
Improving access to specialist care for patients with COPD and asthma
This study is testing a new way to help people with COPD and asthma get better care by connecting them with lung specialists through health coaches, so they can receive helpful advice without having to go to the hospital.
-
Omalizumab for COPD patients with allergen sensitization and exposure
A multicenter trial will test whether adding omalizumab helps people with COPD who are allergic to common indoor allergens and are exposed to them.
-
GLP-1 receptor agonists as immune targets to treat asthma in lean and obese adults
Aims to understand how GLP-1R‑agonist diabetes medicines may directly calm immune cells to reduce asthma in adults who are lean or obese.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.